- Home
- BRDG vs CTNM Comparison
BRDG vs CTNM Comparison
Compare BRDG & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRDG
- CTNM
- Stock Information
- Founded
- BRDG 2009
- CTNM 2009
- Country
- BRDG United States
- CTNM United States
- Employees
- BRDG N/A
- CTNM N/A
- Industry
- BRDG Investment Managers
- CTNM
- Sector
- BRDG Finance
- CTNM
- Exchange
- BRDG Nasdaq
- CTNM Nasdaq
- Market Cap
- BRDG 439.3M
- CTNM 453.0M
- IPO Year
- BRDG 2021
- CTNM 2024
- Fundamental
- Price
- BRDG $10.64
- CTNM $16.07
- Analyst Decision
- BRDG Buy
- CTNM Strong Buy
- Analyst Count
- BRDG 7
- CTNM 3
- Target Price
- BRDG $11.08
- CTNM $28.67
- AVG Volume (30 Days)
- BRDG 240.5K
- CTNM 95.1K
- Earning Date
- BRDG 11-06-2024
- CTNM 11-16-2024
- Dividend Yield
- BRDG 4.87%
- CTNM N/A
- EPS Growth
- BRDG N/A
- CTNM N/A
- EPS
- BRDG N/A
- CTNM N/A
- Revenue
- BRDG $368,472,000.00
- CTNM N/A
- Revenue This Year
- BRDG $42.64
- CTNM N/A
- Revenue Next Year
- BRDG $33.61
- CTNM N/A
- P/E Ratio
- BRDG N/A
- CTNM N/A
- Revenue Growth
- BRDG 27.71
- CTNM N/A
- 52 Week Low
- BRDG $6.18
- CTNM $13.27
- 52 Week High
- BRDG $10.95
- CTNM $22.00
- Technical
- Relative Strength Index (RSI)
- BRDG 68.63
- CTNM N/A
- Support Level
- BRDG $9.93
- CTNM N/A
- Resistance Level
- BRDG $10.76
- CTNM N/A
- Average True Range (ATR)
- BRDG 0.32
- CTNM 0.00
- MACD
- BRDG 0.02
- CTNM 0.00
- Stochastic Oscillator
- BRDG 78.77
- CTNM 0.00
About BRDG Bridge Investment Group Holdings Inc.
Bridge Investment Group Holdings Inc is a vertically integrated investment manager, diversified across specialized asset classes. The company combines its nationwide operating platform with dedicated teams of investment professionals focused on various specialized and synergistic investment platforms, including real estate, credit, renewable energy, and secondaries strategies. Its broad range of products and vertically integrated structure allow it to capture new market opportunities and serve investors with various investment objectives. The company operates Its business in a single segment, alternative investment management, diversified across specialized and synergistic investment platforms.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.